5-Cholesten-3b,25-Diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse models

Molecular Pharmacology

Volumn 83, Issue 3, 2013, Pages 648-658

  Xu, Leyuan ^a   Kim, Jin Koung ^a   Bai, Qianming ^a   Zhang, Xin ^a   Kakiyama, Genta ^a   Min, Hae Ki ^a   Sanyal, Arun J ^a   Pandak, William M ^a   Ren, Shunlin ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHOLESTEN 3BETA,25 DIOL 3 SULFATE; ACETYL COENZYME A CARBOXYLASE; ACETYL COENZYME A CARBOXYLASE 1; ANTILIPEMIC AGENT; CHOLESTEROL; FATTY ACID SYNTHASE; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MESSENGER RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; 25 HYDROXYCHOLESTEROL 3 SULFATE; 25-HYDROXYCHOLESTEROL 3-SULFATE; ACYLTRANSFERASE; AMINOGLYCOSIDE N1 ACETYLTRANSFERASE; AMINOGLYCOSIDE N1-ACETYLTRANSFERASE; CHOLESTEROL DERIVATIVE; CHOLESTEROL ESTER; FAS ANTIGEN; FATTY ACID; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE 2, MOUSE; GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 2, MOUSE; INSULIN; LIPID; SREBF1 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GLUCOSE TOLERANCE; IN VIVO STUDY; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID DIET; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LONG TERM CARE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FATTY LIVER; GENETICS; GLUCOSE TOLERANCE TEST; LIVER; METABOLISM; METHODOLOGY;

ACETYL-COA CARBOXYLASE; ACETYLTRANSFERASES; ANIMALS; ANTIGENS, CD95; CHOLESTEROL ESTERS; DIET, HIGH-FAT; FATTY ACIDS; FATTY LIVER; FEMALE; GENE EXPRESSION; GLUCOSE TOLERANCE TEST; GLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE; HYDROXYCHOLESTEROLS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; LIPID METABOLISM; LIPIDS; LIVER; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TUMOR NECROSIS FACTOR-ALPHA;

MLCS; MLOWN;

EID: 84874323703     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.081505     Document Type: Article

References (57)

1. Abumrad NA and Davidson NO (2012) Role of the gut in lipid homeostasis. Physiol Rev 92:1061-1085.
2. Ahmed MH and Byrne CD (2007) Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today 12:740-747. (Pubitemid 47362786)
3. Ando H, Tsuruoka S, Yamamoto H, Takamura T, Kaneko S, and Fujimura A (2005) Regulation of cholesterol 7alpha-hydroxylase mRNA expression in C57BL/6 mice fed an atherogenic diet. Atherosclerosis 178:265-269. (Pubitemid 40193439)
4. Bai Q, Xu L, Kakiyama G, Runge-Morris MA, Hylemon PB, Yin L, Pandak WM, and Ren S (2011) Sulfation of 25-hydroxycholesterol by SULT2B1b decreases cellular lipids via the LXR/SREBP-1c signaling pathway in human aortic endothelial cells. Atherosclerosis 214:350-356.
5. Bai Q, Zhang X, Xu L, Kakiyama G, Heuman D, Sanyal A, Pandak WM, Yin L, Xie W, and Ren S (2012) Oxysterol sulfation by cytosolic sulfotransferase suppresses liver X receptor/sterol regulatory element binding protein-1c signaling pathway and reduces serum and hepatic lipids in mouse models of nonalcoholic fatty liver disease. Metabolism 61:836-845.
6. Baldán A, Bojanic DD, and Edwards PA (2009) The ABCs of sterol transport. J Lipid Res 50 (Suppl):S80-S85.
7. Basciano H, Miller AE, Naples M, Baker C, Kohen R, Xu E, Su Q, Allister EM, Wheeler MB, and Adeli K (2009) Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis. Am J Physiol Endocrinol Metab 297:E462-E473.
8. Bieghs V, van Gorp PJ, Walenbergh SM, Gijbels MJ, Verheyen F, Buurman WA, Briles DE, Hofker MH, Binder CJ, and Shiri-Sverdlov R (2012) Specific immunization strategies against oxidized low-density lipoprotein: A novel way to reduce nonalcoholic steatohepatitis in mice. Hepatology 56:894-903.
9. Boden G (2006) Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep 6:177-181.
10. Canbay A, Bechmann L, and Gerken G (2007) Lipid metabolism in the liver. Z Gastroenterol 45:35-41. (Pubitemid 46202719)
11. Cha JY and Kim YB (2012) Sulfated oxysterol 25HC3S as a therapeutic target of nonalcoholic fatty liver disease. Metabolism 61:1055-1057.
12. Cha JY and Repa JJ (2007) The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem 282:743-751. (Pubitemid 47076632)
13. Chen G, Liang G, Ou J, Goldstein JL, and Brown MS (2004) Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci USA 101:11245-11250. (Pubitemid 39038332)
14. Chen W, Chen G, Head DL, Mangelsdorf DJ, and Russell DW (2007) Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell Metab 5:73-79. (Pubitemid 44933109)
15. Clark JM, Brancati FL, and Diehl AM (2002) Nonalcoholic fatty liver disease. Gastroenterology 122:1649-1657. (Pubitemid 34533559)
16. Cusi K (2012) Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: Pathophysiology and clinical implications. Gastroenterology 142: 711-725, e6.
17. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ, and Gores GJ (2004) Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 40: 185-194. (Pubitemid 38868937)
18. Ferber D (2000) Lipid research. Possible new way to lower cholesterol. Science 289: 1446-1447.
19. Fuda H, Javitt NB, Mitamura K, Ikegawa S, and Strott CA (2007) Oxysterols are substrates for cholesterol sulfotransferase. J Lipid Res 48:1343-1352. (Pubitemid 47312036)
20. Gill S, Chow R, and Brown AJ (2008) Sterol regulators of cholesterol homeostasis and beyond: The oxysterol hypothesis revisited and revised. Prog Lipid Res 47:391-404.
21. Goldstein JL, DeBose-Boyd RA, and Brown MS (2006) Protein sensors for membrane sterols. Cell 124:35-46.
22. Grefhorst A, Elzinga BM, Voshol PJ, Plösch T, Kok T, Bloks VW, van der Sluijs FH, Havekes LM, Romijn JA, and Verkade HJ et al. (2002) Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 277: 34182-34190.
23. Harney DW and Macrides TA (2008) Synthesis of an isomeric mixture (24RS,25RS) of sodium scymnol sulfate. Steroids 73:424-429.
24. Horton JD, Goldstein JL, and Brown MS (2002) SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109: 1125-1131. (Pubitemid 34496588)
25. Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, and Goldstein JL (2003) Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci USA 100:12027-12032. (Pubitemid 37271509)
26. Ikegami T, Hyogo H, Honda A, Miyazaki T, Tokushige K, Hashimoto E, Inui K, Matsuzaki Y and Tazuma S (2012) Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease. J Gastroenterol 47: 1257-1266.
27. Javitt NB (2008) Oxysterols: Novel biologic roles for the 21st century. Steroids 73: 149-157.
28. Javitt NB, Lee YC, Shimizu C, Fuda H, and Strott CA (2001) Cholesterol and hydroxycholesterol sulfotransferases: Identification, distinction from dehydroepiandrosterone sulfotransferase, and differential tissue expression. Endocrinology 142:2978-2984. (Pubitemid 32575535)
29. Jiang XC, Qin S, Qiao C, Kawano K, Lin M, Skold A, Xiao X, and Tall AR (2001) Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 7:847-852. (Pubitemid 32691641)
30. Korach-André M, Parini P, Larsson L, Arner A, Steffensen KR, and Gustafsson JA (2010) Separate and overlapping metabolic functions of LXRalpha and LXRbeta in C57Bl/6 female mice. Am J Physiol Endocrinol Metab 298:E167-E178.
31. Li J, Viswanadha S, and Loor JJ (2012) Hepatic Metabolic, Inflammatory, and Stress-Related Gene Expression in Growing Mice Consuming a Low Dose of Trans-10, cis-12-Conjugated Linoleic Acid. J Lipids 2012:571281.
32. Li T, Owsley E, Matozel M, Hsu P, Novak CM, and Chiang JY (2010) Transgenic expression of cholesterol 7alpha-hydroxylase in the liver prevents high-fat dietinduced obesity and insulin resistance in mice. Hepatology 52:678-690.
33. Li X, Hylemon P, Pandak WM, and Ren S (2006) Enzyme activity assay for cholesterol 27-hydroxylase in mitochondria. J Lipid Res 47:1507-1512. (Pubitemid 44079904)
34. Li X, Pandak WM, Erickson SK, Ma Y, Yin L, Hylemon P, and Ren S (2007) Biosynthesis of the regulatory oxysterol, 5-cholesten-3beta,25-diol 3-sulfate, in hepatocytes. J Lipid Res 48:2587-2596. (Pubitemid 350272843)
35. Ma Y, Xu L, Rodriguez-Agudo D, Li X, Heuman DM, Hylemon PB, Pandak WM, and Ren S (2008) 25-Hydroxycholesterol-3-sulfate regulates macrophage lipid metabolism via the LXR/SREBP-1 signaling pathway. Am J Physiol Endocrinol Metab 295:E1369-E1379.
36. Malhi H, Bronk SF, Werneburg NW, and Gores GJ (2006) Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 281:12093-12101. (Pubitemid 43855473)
37. Malhi H and Gores GJ (2008) Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 28:360-369.
38. Manco M, Marcellini M, Giannone G, and Nobili V (2007) Correlation of serum TNFalpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol 127:954-960.
39. Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, and Belfiore A (2012) The role of metformin in the management of NAFLD. Exp Diabetes Res 2012: 716404.
40. Neuschwander-Tetri BA (2010) Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites. Hepatology 52:774-788.
41. Ogawa S, Kakiyama G, Muto A, Hosoda A, Mitamura K, Ikegawa S, Hofmann AF, and Iida T (2009) A facile synthesis of C-24 and C-25 oxysterols by in situ generated ethyl(trifluoromethyl)dioxirane. Steroids 74:81-87.
42. Okazaki H, Goldstein JL, Brown MS, and Liang G (2010) LXR-SREBP-1cphospholipid transfer protein axis controls very low density lipoprotein (VLDL) particle size. J Biol Chem 285:6801-6810.
43. Polyzos SA, Kountouras J, and Mantzoros CS (2012) Sulfated oxysterols as candidates for the treatment of nonalcoholic fatty liver disease. Metabolism 61: 755-758.
44. Reddy JK and Rao MS (2006) Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 290: G852-G858.
45. Ren S, Hylemon P, Marques D, Hall E, Redford K, Gil G, and Pandak WM (2004) Effect of increasing the expression of cholesterol transporters (StAR, MLN64, and SCP-2) on bile acid synthesis. J Lipid Res 45:2123-2131. (Pubitemid 40990908)
46. Ren S, Hylemon P, Zhang ZP, Rodriguez-Agudo D, Marques D, Li X, Zhou H, Gil G, and Pandak WM (2006) Identification of a novel sulfonated oxysterol, 5-cholesten-3beta,25-diol 3-sulfonate, in hepatocyte nuclei and mitochondria. J Lipid Res 47: 1081-1090. (Pubitemid 43764704)
47. Ren S, Li X, Rodriguez-Agudo D, Gil G, Hylemon P, and Pandak WM (2007) Sulfated oxysterol, 25HC3S, is a potent regulator of lipid metabolism in human hepatocytes. Biochem Biophys Res Commun 360:802-808. (Pubitemid 47077391)
48. Samuel VT and Shulman GI (2012) Mechanisms for insulin resistance: Common threads and missing links. Cell 148:852-871.
49. Snyder VL, Turner M, Li PK, El-Sharkawy A, Dunphy G, and Ely DL (2000) Tissue steroid sulfatase levels, testosterone and blood pressure. J Steroid Biochem Mol Biol 73:251-256.
50. Tilg H and Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 52:1836-1846.
51. Tiniakos DG, Vos MB, and Brunt EM (2010) Nonalcoholic fatty liver disease: Pathology and pathogenesis. Annu Rev Pathol 5:145-171.
52. Töröcsik D, Szanto A, and Nagy L (2009) Oxysterol signaling links cholesterol metabolism and inflammation via the liver X receptor in macrophages. Mol Aspects Med 30:134-152.
53. Vallim T and Salter AM (2010) Regulation of hepatic gene expression by saturated fatty acids. Prostaglandins Leukot Essent Fatty Acids 82:211-218.
54. van Reyk DM, Brown AJ, Hult'en LM, Dean RT, and Jessup W (2006) Oxysterols in biological systems: Sources, metabolism and pathophysiological relevance. Redox Rep 11:255-262. (Pubitemid 46062350)
55. Xu L, Bai Q, Rodriguez-Agudo D, Hylemon PB, Heuman DM, Pandak WM, and Ren S (2010) Regulation of hepatocyte lipid metabolism and inflammatory response by 25-hydroxycholesterol and 25-hydroxycholesterol-3-sulfate. Lipids 45: 821-832.
56. Xu L, Shen S, Ma Y, Kim JK, Rodriguez-Agudo D, Heuman DM, Hylemon PB, Pandak WM, and Ren S (2012) 25-Hydroxycholesterol-3-sulfate attenuates inflammatory response via PPARg signaling in human THP-1 macrophages. Am J Physiol Endocrinol Metab 302:E788-E799.
57. Zhang Z, Li D, Blanchard DE, Lear SR, Erickson SK, and Spencer TA (2001) Key regulatory oxysterols in liver: Analysis as delta4-3-ketone derivatives by HPLC and response to physiological perturbations. J Lipid Res 42:649-658. (Pubitemid 32367008)